The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
== Safety == Kojic acid may be weakly carcinogenic, according to some animal studies. It is not believed to reach carcinogenic thresholds in human skin, and is demonstrably safe at the level used in cosmetics. In the European Union, the cosmetic use of kojic acid is restricted. Under Commission Regulation (EU) 2024/996, it was added to Annex III of the Cosmetics Regulation (EC) No 1223/2009, permitting it only in face and hand products at a maximum concentration of 1%. The limit applies to products placed on the EU market from 1 November 2025.
Shanimol Osman (born 30 May 1966) is an Indian politician from Kerala. She currently serves as the Deputy Speaker of the Kerala Legislative Assembly. She represents Aroor constituency in the Kerala Legislative Assembly since 21 May 2026. Shanimol is a member of the Indian National Congress.
=== Pusha T's solo career and work relationship with GOOD Music === Before releasing any solo material, Pusha T signed in the autumn of 2010 to GOOD Music, a record label founded by West. That year, he appeared on multiple songs in West's GOOD Fridays series, rapped in the GOOD cypher at the BET Hip Hop Awards, and had two features on West's album My Beautiful Dark Twisted Fantasy. The creative partnership was fruitful; Pusha T became president of GOOD in 2015, and West had production credits on all of his commercially released albums until It's Almost Dry. Pusha T was publicly outspoken about not seeing eye-to-eye with West on politics and career moves multiple times. Among other examples, he expressed disagreement over West's support of Donald Trump and claimed to have different principles on music industry relationships. The relationship had completely deteriorated by late 2022, after West made statements widely condemned as antisemitic. Pusha T said the following in response to West's comments: "It's definitely affected me. It's been disappointing. As a Black man in America, there is no room for bigotry or hate speech. So yeah. It's been very disappointing, let's talk straight." In another interview, he said: "It's beyond [wild stuff] and it's nothing to tap dance around. It's wrong. Period." and "He's not speaking to me now. If you ain't with it, you ain't down. And I ain't with it. I'm not budging on that. I'm not with it." He also clarified that he was no longer the president of GOOD or affiliated with the label in any way.
Sources: en.wikipedia.org
Joseph Berke M.D. (17 January 1939 – 11 January 2021) was an American–born psychotherapist, author of over ten books and lecturer; studied at Columbia College of Columbia University and Albert Einstein College of Medicine; moved to London where he worked with R. D. Laing when Philadelphia Association was being established; was resident at Kingsley Hall; later became an artist and writer; collaborated on a number of projects with Laing, including the Dialectics of Liberation international conference in London; co-founder of the Arbours Association in London and founder and director of Arbours Crisis Centre (1973–2010) in London. He was the author of many articles and books on psychological, social, and religious themes. J. D. Bernal (10 May 1901 – 15 September 1971) was an Irish scientist of Sephardi ancestry who pioneered the use of X-ray crystallography in molecular biology, published on the history of science, wrote popular books on science and society; was a communist activist and a member of the Communist Party of Great Britain (CPGB); his book The World, the Flesh and the Devil called "the most brilliant attempt at scientific prediction ever made" by Arthur C. Clarke. It is famous for having been the first to propose the so-called Bernal sphere, a type of space habitat intended for permanent residence. The second chapter explores radical changes to human bodies and intelligence and the third discusses the impact of these on society.
=== Wound healing === Because galectin-7 is mainly expressed in the stratified epithelia, it is considered a marker of the epidermis, oral cavity, cornea, esophagus, and anorectal epithelium tissues. The injury of corneal wounds causes an increase of sensitivity to receptors of galectin-7 in the cornea. The effect is then blocked by the beta lactose which suggests that the protein's CRD is involved in the stimulatory response to promote the closure of the wound. In a study conducted with mice where the galectin-7 protein was rendered non-functional, the mice were found to have delayed wound closure as the keratinocyte outgrowth was reduced. The study found that the protein localizes to podosomes, a surface in animals that is essential for cell migration and matrix remodeling, and affects the cortactin distribution. The cortactin is a protein that is widely distributed to cellular and in tissue structures which is correlated to the cell's morphology. This would suggest that the protein regulates actin-based lamellipodia formation, a form on the cell that drives cell migration. The kidney epithelial wound repair study found that a non-functional galectin-7 protein results in kidney epithelial cells having a shorter cilia and 33% reduced wound closure, found through various scratch tests. This all indicated how the galectin-7 protein also affects cilia structures and the wound healing process through simple epithelia. The uterine endometrial repair tests expressed how the protein is present and functional in late secretory and menstrual phases.
== Quality == The speed of freezing has a direct impact on the size and the number of ice crystals formed within a food product's cells and extracellular space. Slow freezing leads to fewer but larger ice crystals while fast freezing leads to smaller but more numerous ice crystals. This difference in ice crystal size can affect the degree of residual enzymatic activity during frozen storage via the process of freeze concentration, which occurs when enzymes and solutes present in a fluid medium are concentrated between ice crystal formations. Increased levels of freeze concentration, mediated by the formation of large ice crystals, can promote enzymatic browning. Large ice crystals can also puncture the walls of the cells of the food product which will cause a degradation of the texture of the product as well as the loss of its natural juices during thawing. That is why there will be a qualitative difference observed between food products frozen by ventilated mechanical freezing, non-ventilated mechanical freezing or cryogenic freezing with liquid nitrogen.
==== Philippines ==== In the Philippines, the sweet delicacy tahô is made of fresh tofu (vendors scooped from a wooden bucket with a flat spoon) with brown palm or pandan-flavored sugar syrup and sagó.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.